674 860
[13]
Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohis- tochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012;25:471–9.
[14]
Lalonde E, Alkallas R, Chua ML, et al. Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors. Eur Urol 2017;72:22–31.
[15]
Fraser M, Sabelnykova VY, Yamaguchi TN, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017;541: 359–64.
[16]
Govind SK, Zia A, Hennings-Yeomans PH, et al. ShatterProof: oper- ational detection and quantification of chromothripsis. BMC Bio- informatics 2014;15:78.
[17]
Parker C, Milosevic M, Toi A, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750–7.
[18]
Bo¨ttcher R, Hoogland AM, Dits N, et al. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. Oncotarget 2015;6:4036–50.[19]
Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate can- cer—an ISUP consensus on contemporary grading. APMIS 2016;124:433–5.
[20]
Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 2013;45:1392–8.
[21]
Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high- throughput analysis of SChLAP1. Lancet Oncol 2014;15: 1469–80.[22]
Mehra R, Udager AM, Ahearn TU, et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur Urol 2016;70:549–52.
[23]
Khani F, Epstein JI. Prostate biopsy specimens with Gleason 3 + 3 = 6 and intraductal carcinoma: radical prostatectomy findings and clinical outcomes. Am J Surg Pathol 2015;39:1383–9.
[24]
Chen Z, Chen N, Shen P, et al. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resis- tant prostate cancer. Prostate 2015;75:1247–54.
[25]
Kweldam CF, Ku¨ mmerlin IP, Nieboer D, et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol 2016;29: 630–6.[26]
Milosevic M, Warde P, Me´nard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012;18:2108–14.
[27]
Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K, Fromont G. Clinical significance of epithelial-mesenchymal transition (EMT) markers in prostate cancer. Hum Pathol 2017;61:26–32.
[28]
Chua ML, Bristow RG. Testosterone in androgen receptor signaling and DNA repair: enemy or frenemy? Clin Cancer Res 2016;22: 3124–6.[29]
Tarish FL, Schultz N, Tanoglidi A, et al. Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. Sci Transl Med 2015;7:312re11.
[30]
Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2015;67:326–33.[31]
Zhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol 2016;17:1612–20.[32]
You S, Knudsen BS, Erho N, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res 2016;76:4948–58.[33]
Wei L, Wang J, Lampert E, et al. Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators. Eur Urol 2017;71:183–92.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 6 5 – 6 7 4
674